Northern Trust Company of Connecticut’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Northern Trust Company of Connecticut’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	$19K	Hold	344	–	–	﹤0.01%	1989
2013 Q3	$21K	Hold	344	–	–	﹤0.01%	1965
2013 Q2	$20K	Buy	+344	New	+$21.2K	﹤0.01%	1941

Other funds holding OREX

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCA

SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Company of Connecticut's OREX Position: Q4 2013 in Review

Northern Trust Company of Connecticut held its Orexigen Therapeutics, Inc. (OREX) position steady in Q4 2013 at 344 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #1989.

Northern Trust Company of Connecticut first reported a position in OREX in Q2 2013 and has held it in 3 quarters since. The position peaked at $21K in Q3 2013. 124 funds tracked by Wall St. Rank hold OREX as of Q4 2013.

Northern Trust Company of Connecticut held 344 shares of Orexigen Therapeutics, Inc. worth $19K as of Q4 2013.
Northern Trust Company of Connecticut left its Orexigen Therapeutics, Inc. share count unchanged in Q4 2013.
Orexigen Therapeutics, Inc. made up ﹤0.01% of Northern Trust Company of Connecticut's portfolio in Q4 2013, its #1989 holding.
Northern Trust Company of Connecticut first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and has held it in 3 quarters since.
Northern Trust Company of Connecticut's Orexigen Therapeutics, Inc. position peaked at $21K in Q3 2013.
124 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2013.

Based on Northern Trust Company of Connecticut's 13F filing for Q4 2013, filed 12 Feb 2014.